-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
Meeting News
-
Cell-free RNA Affords Another Tool in Lung Cancer Diagnosis and Treatment Monitoring
Although cell-free DNA (cfDNA) has emerged as the favored nucleic acid to analyze in liquid biopsy samples, there are situations when this marker fails to provided necessary information. In such cases, cell-free RNA (cfRNA) might help fill the void. “Evaluating RNA in liquid biopsies is important because it can be useful for diagnostic, treatment-prediction, or even prognostic purposes,” according to Luis Raez, MD, of the Memorial…
-
Supporting the Detection of Early-Stage Disease with Use of Biomarkers
The NELSON trial and the US National Lung Cancer Screening Trial (NLST) marked major advances in lung cancer by establishing that low-dose computed tomography (LDCT) screening of high-risk individuals is effective at catching the disease in early stages when curative approaches can be used, in turn reducing mortality by 20% to 40%.1,2 The wealth of circulating biomarkers now under investigation begs the question of whether mortality can be reduced further…
-
Leveraging ctDNA to Detect Minimal Residual Disease Following Surgery
Curative therapy remains elusive in early-stage NSCLC following surgical resection, sometimes even for patients with stage I disease. Adjuvant therapy can be of benefit, but only for a select few. As shown in the Lung Adjuvant Cisplatin Evaluation (LACE) meta-analysis, platinum doublet chemotherapy, the current standard of care following complete resection of stage II/III NSCLC, only improved 5-year survival by 5.4%.1 “There is clearly unmet…
-
ctDNA Offers a Window Into Emerging Mechanisms of Resistance to Targeted Therapy
Targeted therapy has undoubtedly transformed the treatment landscape for metastatic NSCLC, with multiple agents now available to target seven different molecular drivers. In tandem with the growing treatment armamentarium, comprehensive molecular profiling has been critical in providing insight into the complexity of a patient’s disease and enabling precision treatment. “Tremendous progress has been made, and I think we are really improving our ability to deliver targeted therapy based on improvements in…
-
Dr. Christian Rolfo Previews the New IASLC Consensus Statement on Liquid Biopsy
In his keynote address during the IASLC 2020 Hot Topic Meeting: Liquid Biopsy, co-chair Christian Rolfo, MD, PhD, MBA, provided an overview of the fastpaced evolution of liquid biopsy. In 2018, at the time of initial discussions, it was only used for treatment-naive patients for whom tissue biopsy was insufficient or after acquired resistance to first- or second-generation EGFR TKIs. Since then groundbreaking research articles…
-
FDA Perspectives on the Use of Liquid Biopsy in NSCLC
The US Food and Drug Administration (FDA) recognizes the value of liquid biopsy in managing patients with cancer, and the agency is actively working to bring these assays to the clinic. Harpreet Singh, MD, Director of the Division of Oncology 2, shed light on past FDA efforts related to approval of liquid biopsy technologies as well as those currently underway. “Liquid biopsies for cancer require close interaction between the oncologist…
-
Biopsy Options Create New Decision-making Points for Clinicians
Understanding the differences in liquid biopsy approaches, as well as how they complement tissue, can be important to therapeutic selection and outcomes.
-
The RAMES Study: A New Strategy of Targeting Angiogenesis in Mesothelioma
At this year’s American Society of Clinical Oncology Virtual Meeting, the final results of the RAMES study were presented.1 RAMES was a prospective, placebo-controlled, phase II, randomized study in which patients with malignant pleural mesothelioma (MPM) that progressed after platinum-based chemotherapy and pemetrexed were assigned to receive gemcitabine 1,000 mg/m2 on Days 1 and 8…
-
Elimination of Clinical Trial Disparities Requires a New Lens for Viewing Justice, New Approach to Patient’s Role
By Joy Curzio Although there has been tremendous progress in lung cancer over the past 10 years, with a number of new drug indications being approved in the United States this year alone, disparities in clinical trial participation look very much the same now as they did a decade or two ago. Janet Freeman-Daily, co-founder…
-
Immunotherapy, TKIs for Resectable/Resected NSCLC: Dr. Masahiro Tsuboi Provides a Comprehensive Overview of Promising Phase II Data, Phase III Status
By Jill Daigneault, PhD Surgical outcomes for early-stage NSCLC are still very poor due to the high rate of recurrence through distant metastases. It is likely that these distant metastases are present at initial resection as undetectable micrometastases. In order to target these potential sites of recurrence in early-stage patients, trials using immunotherapy (IO) and…
View ILCN Archives
Provider Resources
Popular Articles